Rising Treasury yields above 5.3% and the Federal Reserve's September 2026 rate hike have tightened financial conditions, compressing valuations and prompting greater selectivity in IPO pricing amid elevated discount rates. U.S. equity issuance has already reached a record pace in 2026, with approximately $431 billion raised year-to-date through IPOs, follow-ons, and other offerings, though Q3 activity cooled to $93 billion from the prior quarter's peak. Recent smaller deals such as TRex Bio and Retension Pharmaceuticals priced in early October, while a pipeline including Anthropic's targeted November listing and other AI-related filings supports continued flow before year-end. Upcoming catalysts include hyperscaler earnings and any further Fed communications on policy, which could influence risk appetite and aftermarket performance.